A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas

Zeynep Eroglu(Moffitt Cancer Center), Warren Chow(University of California, Irvine)

British Journal of Cancer

April 21, 2015

10.1038/bjc.2015.126

Cited by 37

Related Papers

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

|Annals of Oncology|2016|822

Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies

|Cancer|2016|375

A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report

|Annals of Oncology|2019|5

LBA42 Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma

|Annals of Oncology|2022|0